Amphastar Pharmaceuticals Launches Amphadase

Amphastar Pharmaceuticals, Inc. AMPH announced today that it began shipping Amphadase® (hyaluronidase injection). This launch marks the first product made using starting material from the Company's subsidiary, ANP, located in Nanjing, China. Amphadase® will compete in the hyaluronidase market, which had sales of $23 million for the 12 months ended June 30, 2015, according to IMS Health sales data. Hyaluronidase is an enzyme that breaks down hyaluronic acid in connective tissue, increasing tissue permeability. Hyaluronidase is typically used as an adjunctive agent to facilitate the dispersion and absorption of other drugs. It is used in local anesthesia to increase the area affected and speed the onset of action, especially in nerve-block anesthesia and anesthesia prior to ophthalmic surgery. The Company currently has three abbreviated new drug applications, or ANDAs, filed with the FDA targeting products with a market size of over $0.5 billion, and another ten generic products in development targeting products with a market size of over $15.0 billion. This market information is based on IMS Health sales data for the 12 months ended June 30, 2015. The Company's proprietary pipeline includes a new drug application, or NDA, See full press release